|Drug class||Selective estrogen receptor modulator|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||261.324 g/mol g·mol−1|
|3D model (JSmol)|
NC 45-0095 is a synthetic nonsteroidal selective estrogen receptor modulator (SERM) which was under development by Novo Nordisk for the treatment of postmenopausal osteoporosis but was never marketed. It is a partial agonist of the estrogen receptor (IC50 (for binding inhibition) = 9.5 nM; EC50 = 13 nM) with mixed estrogenic and antiestrogenic activity, and shows full estrogenic activity in bone and uterus (Emax (relative to moxestrol, in Ishikawa endometrial cancer cell line) = 105%). The compound is a pyrroloindolizine derivative. Its development was discontinued by 2003.
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|